Form 4: Zomedica grants 2,126,959 SARs to director Rowe

Zomedica awarded Director Jeffrey M. Rowe 2,126,959 stock appreciation rights at a $0.10 exercise price, exercisable from November 16, 2026 and expiring November 16, 2035.

Summary

• On 2025-11-17, Director Jeffrey M. Rowe received 2,126,959 Stock Appreciation Rights (SARs) from Zomedica Corp. (ZOMDF).
• Exercise price per SAR is $0.10; no cash was paid for the grant.
• The SARs become exercisable on 2026-11-16 and expire on 2035-11-16.
• Underlying common shares tied to the SARs total 2,126,959.
• Following the grant, Rowe directly beneficially owns 2,126,959 derivative securities.

Sentiment

Score: 5

Explanation: Neutral insider equity grant that aligns incentives but contains no operational or financial performance updates.

Positives

• Equity award strengthens alignment between a board member and shareholders.
• Long-dated expiration (2035-11-16) supports a long-term value-creation horizon.
• Fixed exercise price of $0.10 ensures value is realized only if the share price appreciates.

Negatives

• Potential dilution for existing shareholders if the SARs are exercised and settled in shares (up to 2,126,959 shares).
• No operational or financial performance information accompanies the insider award.

Future Outlook

No forward-looking statements or guidance disclosed.

Industry Context

Director-level equity awards are standard across U.S.-listed small-cap healthcare companies. SARs with approximately one-year initial exercisability and 10-year terms are common structures used to align governance incentives without immediate cash outlay.

Comparison to Industry Standards

• Relative to larger peers such as IDEXX Laboratories (IDXX) and Elanco (ELAN), which commonly use RSUs for director compensation, SARs are more typical among small-cap issuers; the 10-year term and ~1-year initial exercisability align with common market practice.
• Grant sizing cannot be benchmarked here without share price and market cap context; structurally, the fixed exercise price and long-dated expiration match standard designs in healthcare small caps.

Related Party Transactions

• Equity compensation grant of 2,126,959 SARs at a $0.10 exercise price to Director Jeffrey M. Rowe.

Stakeholder Impact

• Aligns director incentives with shareholder value through performance-linked equity.
• Could lead to share issuance upon exercise, potentially diluting existing shareholders by up to 2,126,959 shares depending on settlement method.

Next Steps

• SARs become exercisable on 2026-11-16.
• Unexercised SARs will expire on 2035-11-16.

Key Dates

Keywords

Zomedica, ZOMDF, Form 4, Insider transaction, Stock Appreciation Rights, SAR grant, Jeffrey M. Rowe, Director compensation, Equity award, Veterinary diagnostics